Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%
Market cap
$181.1B
P/E
33.9×
Fwd P/E
22.9×
Dividend yield
2.40%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100

Abbott Laboratories (ABT) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Abbott Laboratories (ABT) trades at a EV/FCF of 26.8×. Over the past ten years it has ranged from 20.3× (October 2022) to 47.2× (November 2020); the current reading is higher than 22% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 30.0× (6.01%)
FY2024 32.0× (18.57%)
FY2023 39.2× 54.14%
FY2022 25.5× (14.53%)
FY2021 29.8× (17.03%)
FY2020 35.9× (3.51%)
FY2019 37.2× 28.16%
FY2018 29.0× 6.94%
FY2017 27.1× (5.14%)
FY2016 28.6× (20.64%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 23.6× (15.20%)
Mar 2026 27.9× (7.20%)
Dec 2025 30.0× (12.91%)
Sep 2025 34.5× (3.96%)
42 more quarters

Against its own ten years

Low 20.3× High 47.2×
Ten-year median 31.6×
Current reading's percentile 22

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on ABT